Rep. Jared Moskowitz Sells Shares of STERIS plc (NYSE:STE)

Key Points

• Rep. Jared Moskowitz sold between $1,001 and $15,000 of STERIS stock on July 13, 2026, from a Morgan Stanley Active Assets account. He also sold W.W. Grainger and purchased shares of companies including Applied Materials, Microsoft, HCA Healthcare, Home Depot and Meta Platforms.
• STERIS reported quarterly EPS of $2.59, beating estimates by $0.10, while revenue rose 7.3% year over year to $1.49 billion. The company raised its quarterly dividend to $0.69, equivalent to a 1.2% annual yield.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $271.33, compared with the stock’s reported opening price of $230.56. Separately, company insiders sold 6,851 shares worth about $1.55 million over the past three months.

Representative Jared Moskowitz (Democratic-Florida) recently sold shares of STERIS plc NYSE: STE. In a filing disclosed on August 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 13th. The trade occurred in the Representative's "MORGAN STANLEY ACTIVE ASSETS (1)" account.

Representative Jared Moskowitz also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of W.W. Grainger NYSE: GWW on 7/13/2026.
• Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 7/13/2026.
• Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 6/18/2026.
• Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 6/17/2026.
• Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 6/17/2026.
• Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 6/17/2026.
• Purchased $1,001 - $15,000 in shares of Monster Beverage NASDAQ: MNST on 6/17/2026.
• Sold $1,001 - $15,000 in shares of S&P Global NYSE: SPGI on 6/17/2026.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 6/17/2026.
• Purchased $1,001 - $15,000 in shares of SpaceX NASDAQ: SPCX on 6/12/2026.

STERIS Stock Up 0.4%

Shares of NYSE STE opened at $230.56 on Thursday. The stock has a market capitalization of $22.48 billion, a price-to-earnings ratio of 28.19 and a beta of 0.91. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The firm has a 50-day moving average price of $224.83 and a 200 day moving average price of $222.42. The company has a quick ratio of 1.35, a current ratio of 1.91 and a debt-to-equity ratio of 0.23.

STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.49 by $0.10. The company had revenue of $1.49 billion during the quarter, compared to analysts' expectations of $1.49 billion. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The firm's quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the company posted $2.34 earnings per share. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Equities research analysts anticipate that STERIS plc will post 11.09 EPS for the current fiscal year.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, September 4th will be paid a $0.69 dividend. This represents a $2.76 annualized dividend and a dividend yield of 1.2%. This is a positive change from STERIS's previous quarterly dividend of $0.63. The ex-dividend date is Friday, September 4th. STERIS's dividend payout ratio (DPR) is 33.74%.

Insiders Place Their Bets

In other news, Director Mohsen Sohi sold 4,058 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total transaction of $956,795.24. Following the sale, the director owned 24,305 shares in the company, valued at $5,730,632.90. This trade represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP John Adam Zangerle sold 1,419 shares of STERIS stock in a transaction on Monday, June 15th. The shares were sold at an average price of $209.28, for a total value of $296,968.32. Following the completion of the sale, the vice president directly owned 35,259 shares of the company's stock, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 6,851 shares of company stock valued at $1,545,052. Company insiders own 1.12% of the company's stock.

Institutional Trading of STERIS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Activest Wealth Management boosted its stake in shares of STERIS by 423.8% during the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 89 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in shares of STERIS in the fourth quarter valued at approximately $28,000. Western Wealth Management LLC purchased a new position in shares of STERIS during the first quarter valued at approximately $25,000. Cornerstone Planning Group LLC lifted its stake in shares of STERIS by 342.3% during the fourth quarter. Cornerstone Planning Group LLC now owns 115 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 89 shares during the period. Finally, Elevation Wealth Partners LLC boosted its position in STERIS by 1,130.0% during the second quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 113 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on STE shares. Wall Street Zen raised STERIS from a "hold" rating to a "buy" rating in a research note on Sunday, August 9th. Weiss Ratings restated a "hold (c)" rating on shares of STERIS in a research report on Monday, August 24th. KeyCorp decreased their price objective on shares of STERIS from $291.00 to $269.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 13th. UBS Group reduced their price target on shares of STERIS from $275.00 to $270.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $275.00 price target (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, STERIS presently has a consensus rating of "Moderate Buy" and a consensus target price of $271.33.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida's 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 23rd Congressional District. He declared candidacy for the 2026 election. Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor's degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz's career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

STERIS Company Profile

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source